Cannabidiol (CBD) and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial
Conclusions: In this randomized double-blind clinical trial of healthy adults administered CBD, 5mg/kg/d for 28 days, 8 (5.6%) experienced liver enzyme level elevations and 7 (4.9%) met protocol defined criteria for potential DILI. This research has important implications for consumer safety. The findings suggest that CBD use at doses representative of currently available unregulated consumer products can lead to liver enzyme level elevations in healthy adults.
As CBD users may not notice these changes on their own, this study highlights the need for caution and potentially routine monitoring in CBD users. The incidence of elevated alanine aminotransferase or aspartate aminotransferase, with a notably higher prevalence among female participants, coupled with the finding of increased eosinophilia, underscores the need for further investigation on the long-term effects of CBD use, its impact on various populations, and the safety of lower doses commonly used by consumers.
